Development of lozenge formulation of passiflora incarnata

The main purpose of the development of chewable and soft lozenge dosage formulation containing passiflora incarnata extract as a sleeping agent is to provide an individual dosage form. The other purpose of this study the lozenge formulation is developed for people who suffer from basically insomnia and sleeping disorder based on anxiety. In this study, passiflora incarnata extract is used in developed different lozenge and edible film formulation due to ease of administration, non-invasiveness, adaptability, patient compliance and acceptability of this dosage form. Thus the optimum formulation development of lozenge form is studied and evaluated. The P7 formulation is chosen and this chewable lozenge formulation has composed of 40% glycerin, 15% gelatin, 35% purified water and 10% passiflora incarnata extract and it has a pleasant taste for serving purpose of the development. The vitexin amount is analyzed and the efficient lozenge formulation of the passiflora incarnata extract can be demonstrated . The P7 formulation is analyzed and according to HPLC study results the P7 passiflora incarnata lozenge dosage formulation was containing 1.358 mg/g (n=6) of vitexin. A month later, vitexin amount was found around 1.301mg/g (n=6). The taste was masked with simple syrup. As a result of this outcomes, the chewable lozenge formulation was containing 1.3% vitexin and P7 lozenge formulation will be possible promising optional dosage form for treatment of sleeping disorder problem.